Chronic Lymphocytic Leukemia Research Consortium

慢性淋巴细胞白血病研究联盟

• 批准号: 8063833
• 负责人: Thomas J Kipps
• 金额: $ 11.67万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8063833
• 关键词: Accounting; Active Immunotherapy; Antigens; Antineoplastic Agents; Apoptosis; Biochemical; Biostatistics Core; Cells; Chronic Lymphocytic Leukemia; Clinic; Clinical; Clinical Research; Clinical Trials; Databases; Defect; Development; Disease; Generations; Genetic; Immune response; Information Systems; Investigation; Laboratories; Maintenance; Monitor; New Agents; Participant; Patients; Pharmacology; Phase; Predisposition; Research; Research Infrastructure; Research Personnel; Sampling; Secure; Staging; T-Lymphocyte; Techniques; Testing; Therapy Evaluation; Tissue Banking; Tissue Banks; Tissues; Translating; Validation; base; cell mediated immune response; data exchange; design; gene therapy; improved; leukemia; member; novel; programs; protein expression; response; trafficking; tumor

DESCRIPTION (provided by applicant): The CLL Research Consortium (CRC) is multi-institutional program, investigating the biologic basis of CLL and novel biologic and pharmacologic treatments for this disease, which enables CRC investigators to function beyond the capacities of any single member. It provides for uniform, high-volume sample accrual to a sophisticated national tissue bank, secured on-line information systems, and an infrastructure that facilitates the research on novel therapies and the evaluation of clinical-laboratory relationships that improve clinical staging and/or that assist in the early assessment of response to novel therapies. The CRC has six major projects. Project 1 investigates the genetic basis for CLL and the development of novel probes that can translate genetic discoveries into the clinic. Project 2 investigates the leukemia cell expression of proteins that regulate susceptibility to apoptosis and novel compounds that can interfere with their biochemical function. Project 3 examines for leukemia-associated antigens and novel techniques for active immunotherapy of this disease, including gene therapy. Project 4 examines the mechanism(s) accounting for ineffective T cell mediated immune response against putative leukemia-cell antigens and evaluates for specific T cell defects that can interfere with development of effective anti-tumor cellular immune responses. Project 5 focuses on promising anticancer agents for phase l/ll testing in patients with CLL and examines the activity of these agents acting alone or in mechanism-based combinations. Project 6 is a new project that examines the pharmacology of promising new agents for treatment of this disease. The CRC has 4 cores: The administrative core coordinates research investigations, oversees the generation and maintenance of the clinical and laboratory databases and information systems, and facilitates information and data exchange between program participants. The Biostatistics Core assists investigators in the design and interpretation of basic and clinical research. The Tissue Core is responsible for tissue banking, sample trafficking, and leukemia-sample laboratory testing and sample-validation. The Clinical Core helps develop, implement, execute, monitor, and analyze CRC clinical trials.

描述（由申请人提供）：CLL研究联盟（CRC）是多机构计划，研究了该疾病的CLL和新型生物学和药理治疗的生物学基础，这使CRC研究人员能够超出任何单个成员的能力。 它为复杂的国家组织库提供了统一的，大量的样本，确保在线信息系统和基础设施，促进了有关新型疗法的研究以及评估临床实验室关系的研究，从而改善了临床分期和/或有助于对新治疗的早期评估。 CRC有六个主要项目。 项目1研究了CLL的遗传基础和可以将遗传发现转化为诊所的新型探针的发展。 项目2研究了调节细胞凋亡的易感性和可干扰其生化功能的新型化合物的蛋白质的白血病细胞表达。 项目3研究了白血病相关的抗原和该疾病主动免疫疗法的新技术，包括基因治疗。 项目4检查了针对假定的白血病抗原的无效T细胞介导的免疫反应的机制，并评估可能干扰有效抗肿瘤细胞免疫反应的特定T细胞缺陷。 项目5专注于CLL患者的有希望的抗癌剂，用于L/LL测试，并检查这些单独或基于机制组合的药物的活性。 项目6是一个新项目，研究了有望治疗该疾病的新药物的药理学。 CRC有4个核心：行政核心坐标研究调查，监督临床和实验室数据库和信息系统的生成和维护，并促进计划参与者之间的信息和数据交换。生物统计学核心协助研究人员的基础研究和临床研究的设计和解释。 组织核心负责组织库，样品运输和白血病样品实验室测试和样品验证。 临床核心有助于开发，实施，执行，监测和分析CRC临床试验。